Baipharm
ChemLinkedMarketChemicalFoodCosmeticBaiPharm Agrochemical Japan
News
Comprehensive coverage on the latest pharmaceutical regulatory update and industry activities in China.
POLICY
NRDL Health Insurance New Drug COVID-19
[Updated] China Adds 111 Drugs to 2022 National Reimbursement Drug List On Mar. 1, 2023, China starts to implement the 2022 National Reimbursement Drug List (NRDL), a list of drugs fully or partially reimbursed by the national basic health insurance.
Mar 01, 2023
POLICY
Cancer Rare Disease COVID-19
China Levies Zero Tariff on Active Pharmaceutical Ingredients of COVID-19, Cancer, and Rare Disease Drugs According to China's 2023 Tariff Adjustment Plan, tariffs are provisionally lowered to zero for 22 categories of active pharmaceutical ingredients of medicines for treating COVID-19, cancer, and rare diseases.
Jan 05, 2023
POLICY
Cancer Rare Disease
China to Cut VAT on the 3rd List of Anti-cancer and Rare Disease Drugs China will reduce the VAT to 3% for a list of anti-cancer drugs and rare disease / orphan drugs from Dec. 1, 2022.
Nov 25, 2022
POLICY
Volume-based Procurement
China Unveils the Final Drug List for the 7th Volume-based Procurement (VBP) On July 18, China announced the official list of 327 products for the 7th volume-based procurement (VBP).The 327 products are owned by 217 bid-winning companies, which will supply the products to public health institutions. Among the companies, 6 are international enterprises—Hetero Labs, Bracco Sine, Almirall, Sandoz, and Pfizer.
Jul 25, 2022
POLICY
Volume-based Procurement
327 Drug Products to Enter China's 7th Round of Volume-based Procurement (VBP) Six international pharma companies--Hetero Labs, Bracco Sine, Almirall, Sandoz, Astellas, and Pfizer--won the bid in the preliminary result of the China's 7th round of volume-based procurement (VBP) of drugs.
Jul 15, 2022
POLICY
NRDL Cancer Rare Disease
China Emphasizes Rare Disease & Pediatric Drugs in Adjusting the 2022 National Reimbursement Drug List (NRDL) On June 29, 2022, China NHSA issued the Work Plan for Adjusting the 2022 National Reimbursement Drug List (NRDL). NRDL is a list of drugs covered by the basic national insurance for healthcare, employment injury, and maternity.
Jul 04, 2022
POLICY
Volume-based Procurement
China Kicks off the 7th Round of Volume-based Procurement (VBP) of Drugs On June 20, China National Joint Drug Procurement Office announced the start of the 7th round of volume-based procurement (VBP), covering 59 drugs with different active pharmaceutical ingredients.
Jun 24, 2022
POLICY
Innovative Drug New Drug COVID-19
China Adds Pfizer's Paxlovid to Diagnosis and Treatment Protocol for COVID-19 Pneumonia China has added Brii Bio’s Amubarvimab/Romlusevimab Combination and Pfizer’s Paxlovid to the Diagnosis and Treatment Protocol for COVID-19 Pneumonia (9th Trial Version).
Mar 23, 2022
POLICY
Law & Regulation Marketing Approval Volume-based Procurement Health Insurance Innovative Drug Cancer Cardiovascular Disease Rare Disease Drug Registration New Drug
China's 2022 Two Sessions: Goals and Proposals for Pharma & Healthcare Industry China's Government Work Report says one off the major tasks for 2022 is to improve medical and health services.
Mar 15, 2022
POLICY
NRDL Health Insurance Innovative Drug Cancer Rare Disease
China Adds 74 Drugs to National Reimbursement Drug List (NRDL) On Dec. 3, China released its 2021 National Reimbursement Drug List (NRDL). NRDL is a list of drugs allowable for reimbursement by the national social health insurance fund under the social security system which has covered more than 1.36 billion people in China by the end of 2020.
Dec 08, 2021
123 Next
Most Popular